A real-world analysis of adverse events and operational impacts of using T-cell engager therapy in an oncology setting

Shalini Fernandes, Diya Nijjar, Lollita Rahaman, Shannon Farley, Sabiha Delawala

Abstract


Background: T-cell engager (TCE) therapies are an emerging immunotherapy option for hematologic malignancies and small-cell lung cancer. While effective, they are associated with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), particularly during ramp-up dosing. Evidence to guide nursing assessment, monitoring, and operational planning in real-world settings remains limited.

Purpose: To describe the frequency, severity, timing, and management of CRS and ICANS among patients receiving TCE therapy at a community hospital oncology program, and to explore operational impacts, such as length of stay and geographic considerations.

Methods: A retrospective chart review of 30 patients who received TCE therapy at the Osler Oncology Program at Brampton Civic Hospital between August 2023 and May 2025 was conducted. Demographic, treatment, adverse event, and operational data were abstracted from electronic medical records using standardized forms. Cytokine release syndrome and ICANS were graded using American Society for Transplantation and Cellular Therapy (ASTCT) criteria. Descriptive statistics were used to summarize outcomes.

Results: Cytokine release syndrome occurred in 77% (23/30) of patients, predominantly Grade 1 (70% of CRS cases), with most events occurring within 24 hours of ramp-up dosing and primarily following Dose 1. Immune effector cell-associated neurotoxicity syndrome occurred in 27% (8/30) of patients, including one Grade 4 event. Seventy-five percent of ICANS cases occurred in patients who also experienced CRS. Early use of tocilizumab for Grade 1 CRS appeared to reduce progression to higher grades. Mean total length of stay across ramp-up dosing was 11.4 days, decreasing from 7.2 days for the initial visit to 1.6 days for Dose 3.

Conclusions: T-cell engager therapy in a community oncology setting is feasible but requires structured nursing assessment protocols, intensive early monitoring, and evolving management strategies. Findings support exploration of risk-stratified outpatient models for selected patients.

Keywords: T-cell engager therapy, cytokine release syndrome, ICANS, oncology nursing, tocilizumab, outpatient oncology

https://doi.org/10.5737/23688076362350


Full Text:

PDF

References


Ahn, M. J., Cho, B. C., Felip, E., Korantzis, I., Ohashi, K., Majem, M., Juan-Vidal, O., Handzhiev, S., Izumi, H., Lee, J. S., Dziadziuszko, R., Wolf, J., Blackhall, F., Reck, M., Bustamante Alvarez, J., Hummel, H. D., Dingemans, A. C., Sands, J., Akamatsu, H., … DeLLphi-301 Investigators. (2023). Tarlatamab for patients with previously treated small-cell lung cancer. The New England Journal of Medicine, 389(22), 2063–2075. https://doi.org/10.1056/NEJMoa2307980

Albayrak, G., Wan, P. K., Fisher, K., & Seymour, L. W. (2025). T cell engagers: Expanding horizons in oncology and beyond. British Journal of Cancer. Advance online publication. https://doi.org/10.1038/s41416-025-03125-y

Amgen Canada Inc. (2024). Imdelltra. Retrieved May 7, 2025, from https://dhpp.hpfb-dgpsa.ca/dhpp/resource/104030

BC Cancer. (2025). Bispecific antibodies. http://www.bccancer.bc.ca/health-professionals/clinical-resources/chemotherapy-protocols/immunotherapy/bispecific-antibodies

Cech, P., Skórka, K., Dziki, L., & Giannopoulos, K. (2024). T-cell engagers—The structure and functional principle and application in hematological malignancies. Cancers, 16(8), 1580. https://doi.org/10.3390/cancers16081580

Goebeler, M.-E., & Bargou, R. C. (2020). T cell–engaging therapies: BiTEs and beyond. Nature Reviews Clinical Oncology, 17(7), 418–434. https://doi.org/10.1038/s41571-020-0347-5

Hoffman-La Roche Limited. (2023). Columvi. Retrieved May 7, 2025, from https://dhpp.hpfb-dgpsa.ca/dhpp/resource/102531

Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2015). Bispecific T-cell engagers for cancer immunotherapy. Immunology and Cell Biology, 93(3), 290–296. https://doi.org/10.1038/icb.2014.93

Janssen Inc. (2024). Talvey. Retrieved June 2, 2025, from https://www.janssenlabels.com/ca/content/labelling/TALVEY/talvey_cpm.pdf

Janssen Inc. (2023). Tecvayli. Retrieved May 7, 2025, from https://pdf.hres.ca/dpd_pm/00071837.PDF

Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., Go, W. Y., Eldjerou, L., Gardner, R. A., Frey, N., Curran, K. J., Peggs, K., Pasquini, M., DiPersio, J. F., van den Brink, M. R. M., … Neelapu, S. S. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25(4), 625–638. https://doi.org/10.1016/j.bbmt.2018.12.758

Martin, T. G., Mateos, M. V., Nooka, A., Banerjee, A., Kobos, R., Pei, L., Qi, M., Verona, R., Doyle, M., Smit, J., Sun, W., Trancucci, D., Uhlar, C., van de Donk, N. W. C. J., & Rodriguez, C. (2023). Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. Cancer, 129(13), 2035–2046. https://doi.org/10.1002/cncr.34756

Pfizer Canada ULC. (2023). Elrexfio. Retrieved May 7, 2025, from https://www.pfizer.ca/en/our-products/elrexfio-elranatamab-injection

Sands, J., Smith, A. B., Johnson, C. D., & Brown, E. F. (2024, September 7–10). Efficacy and safety of a novel bispecific antibody in advanced non-small cell lung cancer: Results from a phase II trial [Conference presentation]. World Conference on Lung Cancer, San Diego, CA, United States.

Scott, S. A., Marin, E. M., Maples, K. T., Joseph, N. S., Hofmeister, C. C., Gupta, V. A., Dhodapkar, M. V., Kaufman, J. L., Lonial, S., & Nooka, A. K. (2023). Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood Cancer Journal, 13(1), 191. https://doi.org/10.1038/s41408-023-00963-y

Stief, S. M., Hanneforth, A. L., Weser, S., Mattes, K., Carlet, M., Liu, W. H., Barth, T. F., Koerner, S. P., Kroell, T., Schlaak, A., Schmohl, J. U., Malenke, E., Kanz, L., Brauer, K. M., Mocikat, R., Jung, G., Salih, H. R., & Loefler, H. (2020). Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. Journal for Immunotherapy of Cancer, 8(1), e000621. https://doi.org/10.1136/jitc-2020-000621


Refbacks

  • There are currently no refbacks.


Bookmark and Share